25th Mar 2015 10:28
LONDON (Alliance News) - Biofrontera AG on Wednesday said it has now taken over sales and marketing activity for its Ameluz and BF-RhodoLED products in Spain from Allergan Pharmaceuticals.
Ameluz is a prescription drug for the treatment of superficial skin cancer, while BF-RhodoLED is a photodynamic therapy lamp.
"Spain is one of the most important European markets for photodynamic therapy," said Chief Executive Hermann Lübbert. "In the new structure, we can now collect the entire margin of the Ameluz sales for Biofrontera. Thus, our profitability in Spain will increase significantly. It is anticipated that the additional investment in sales and marketing should pay off within one year."
Shares in Biofrontera were up 2.3% to 220.00 pence in London on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L